Correction: COVID-19 and its effects on endothelium in HIV-positive patients in sub-saharan Africa: cardiometabolic risk, thrombosis and vascular function (ENDOCOVID STUDY)
Correction: COVID-19 and its effects on endothelium in HIV-positive patients in sub-saharan Africa: cardiometabolic risk, thrombosis and vascular function (ENDOCOVID STUDY)
By: Nandu Goswami, Per Morten Fredriksen, Knut E. A. Lundin, Chidozie Agu, Simiat Olanike Elias, Keolebogile Shirley Motaung, Bianca Brix, Gerhard Cvirn, Harald Sourij, Evelyn Stelzl, Harald H. Kessler, Adam Saloň and Benedicta Nkeh-Chungag
Publication: BMC Infectious Diseases; 15 February 2024. DOI: https://doi.org/10.1186/s12879-021-06426-8
COVID-19 has significantly impacted health systems and economies worldwide, particularly in sub-Saharan Africa, where the interaction between HIV infection and non-communicable diseases like cardiovascular disease is prevalent. The role of HIV and antiretroviral treatment (ART) in cardiovascular risk remains unclear, and the impact of COVID-19 co-infection in people living with HIV (PLHIV) needs further research. The ENDOCOVID project aims to investigate how HIV infection in COVID-19 patients affects the disease’s progression, cardiovascular risk, and vascular endothelial function and coagulation parameters. The study will include 1,026 patients, with groups of PLHIV with and without ART and HIV-negative individuals, all with COVID-19. Researchers will measure cardiovascular risk factors and biomarkers, vascular and endothelial function, and coagulation markers at various stages, including admission, weekly, discharge, and four weeks post-discharge. The project aims to assess the long-term cardiovascular risk and endothelial function in PLHIV, revealing an important transitional cardiovascular phenotype in COVID-19 patients.